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Abstract
Background: Oncolytic virus which arms the therapeutic gene to enhance anti-tumor activity is a prevalent
strategy to improve oncovirotherapy of cancer. Newcastle disease virus (NDV) is a naturally oncolytic virus used for
cancer therapy. Previously, we generated a mouse-human chimeric HAb18 antibody (cHAb18) against tumor-
associated antigen CD147 and demonstrated the inhibition of invasion and migration of hepatocellular carcinoma
(HCC) cells. Here, we constructed a recombinant NDV carrying intact cHAb18 gene (rNDV-18HL) based on Italien
strain using a reverse genetics system.
Method: Recombinant rNDV-18HL was generated using reverse genetics technology. The characteristics of virally
expressed cHAb18 antibody were identified by western blot, enzyme-linked immunosorbent assay, transwell
invasion assay, and surface plasmon resonance technology. The biodistribution of recombinant rNDV-18HL using
orthotopic xenograft mouse model was assessed with living imaging and immunohistochemistry. Kaplan-Meier
survival curves and the log-rank test were performed to analyze the anti-tumor activity of rNDV-18HL.
Results: The cHAb18 was produced in rNDV-18HL-infected cells followed by releasing into the supernatant by
cytolysis. The rNDV-18HL-encoded cHAb18 antibody kept affinity for CD147 and showed inhibiting the migration
and invasion of HCC cells. Viral replication and virulence were not attenuated by the incorporation of cHAb18 gene
which significantly enhanced the suppression of relict tumor cell migration. The rNDV-18HL selectively replicated in
orthotopic HCC xenografts leading to cHAb18 expression in situ, which induced the tumor necrosis, reduced the
intrahepatic metastasis, and prolonged the survival in mice.
Conclusions: This study provides a new strategy of arming oncolytic NDV with therapeutic antibody to enhance
anti-tumor efficacy of cancer therapy.
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Background
Oncolytic virus (OV) has the special property with se-
lective infection of tumor cells, leading to oncolysis of
cancer cells and minimal toxicity to normal tissues,
which is administrated in cancer therapy called oncolytic
virotherapy. A great variety of OVs, including genetically
engineered and natural viruses have shown promise in
preclinical models and clinical studies [1].
NDV is a member of the Paramyxoviridae with a
negative non-segment single strand RNA genome which
encodes six proteins including nucleocapsid protein
(NP), phosphoprotein (P), matrix protein (M), fusion
protein (F), haemagglutinin-neuraminidase (HN), and
RNA dependent RNA polymerase (L). NDV strains are
classified into velogenic (highly virulent), mesogenic
(intermediate virulence), and lentogenic (nonvirulent)
based on the virulence in the natural host [2]. The virus
is regarded as a natural OV for solid tumor therapy in
clinic trials and shows minimal side-effects with systemic
administration [3, 4]. Recently, the toxicity, biodistribu-
tion, and shedding of NDV in non-human primates
under intravenous injection were evaluated, demonstrat-
ing the safety for intravenous administration [5].
In a previous study, we identified NDV Italien strain
belonged to the velogenic strain [6]. By reverse genetics
technology, we demonstrated that NDV Italien was able
to carry exogenous genes without affecting virus replica-
tion [7]. The results suggest that NDV Italien can be
served as a candidate vector carrying therapeutic trans-
genes to enhance the therapeutic indices for armed
oncolytic virotherapy of cancers.
Several recombinant OVs, such as herpes simplex
virus (HSV) [8, 9], vaccinia virus [10], and vesicular
stomatitis virus [11] are armed with granulocyte-
macrophage colony-stimulating factor (GM-CSF) to
enhance systemic anti-tumor immune response. OncoV-
EXGM-CSF, a recombinant HSV expressing GM-CSF in
phase III trial for treatment of melanoma, was proved to
eliminate cancer cells by inducing local and systemic
antigen-specific T cell responses and decreasing suppres-
sive immune cell populations [12]. In October 2015, the
US Food and Drug Administration approved the inject-
able formulation of OncoVEXGM-CSF, with the brand
name Imlygic, for the treatment of melanoma in patients
with inoperable tumors.
Therapeutic antibodies have achieved considerable
success in treating patients with haematological malig-
nancies and solid tumors. The mechanisms of tumor cell
killing by antibodies are summarized as the direct action
of the antibody, payload delivery, and specific effects of
an antibody on the tumor vasculature and stroma. Intact
antibody can also trigger antibody-dependent cellular
cytotoxicity and complement-dependent cytotoxicity,
which improve the antitumor therapeutic effect greatly.
Several monoclonal antibody drugs, such as trastuzu-
mab, bevacizumab, and DTA-1 are used in the combin-
ation therapy with OVs to enhance the antitumor
efficacy in recent years [13–15]. Another strategy is to
construct recombinant OVs which express antibody as
an effector to augment the cytotoxicity of OVs. A re-
combinant oncolytic adenovirus expressing anti-CTLA4
antibody was generated and showed an effective antitu-
mor activity in vivo [16].
Previously we developed a murine monoclonal anti-
body, HAb18 (generic named metuximab) targeting
CD147 molecule. CD147 is over-expressed in HCC cells
and involved in tumor cell invasion [17] and closely re-
lated to prognosis in patients with HCC [18–22]. Iodine
[131I] metuximab injection was approved in China for
treatment of HCC in 2005. It has been proved to have a
beneficial treatment effect on prevention of tumor recur-
rence in patients with HCC [23, 24]. We generated a
mouse-human chimeric cHAb18 antibody that derived
from murine HAb18 and showed inhibition of HCC cell
invasion and migration [25].
In order to combine the direct oncolysis induced by
NDV with the antibody-targeted therapy, we here con-
structed a recombinant NDV Italien carrying a chimeric
cHAb18 gene which expressed intact antibody in tumor
tissue along with viral replication. The results showed
that the recombinant NDV inhibited the intrahepatic
metastasis of HCC and prolonged the survival in ortho-
topic hepatoma-bearing mice.
Methods
Cell lines and viruses
The BSR-T7/5 cell line was kindly donated by Prof.
Karl-Klaus Conzelmann (Ludwig Maximilian University,
Munich, Germany). SMMC-7721, HepG2, HuH-7, and
BHK-21 cell lines were purchased from the Cell Bank of
the Chinese Academy of Sciences (Shanghai, China). All
cells were grown in Dulbecco’s Modified Eagle Medium
(GE healthcare, Little Chalfont, UK) with 10 % fetal
bovine serum and maintained at 37 °C in a humidified
incubator supplied with 5 % CO2.
The NDV Italien strain was obtained from Prof.
Volker Schirrmacher (German Cancer Research Center,
Heidelberg, Germany) and prepared as reported previ-
ously [6]. The recombinant rNDV-Luci which expressed
firefly luciferase was generated based on Italien strain in
our previous works [7].
Generation of recombinant rNDV-18HL
The gene of chimeric antibody cHAb18 was cloned from
the plasmid 18HL-pDHL which was constructed in our
previous study [25]. The light and heavy chains were
cloned respectively using primer pairs 18 L-F/R and
18H-F/R (Table 1) and then joined by overlap extension
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PCR. The annealed fragment was provided with an extra
gene start (GS) and gene end (GE) sequences and
flanked on either side with a Kpn2I restriction site as
shown in Fig. 1a. The PCR products were purified with a
gel extraction kit (Omega Bio-Tek, Norcross, NA) and
cloned into pBR-rNDV which was constructed based on
the NDV Italien in our previous study [7] using the AgeI
restriction site. The resulting plasmid was named pBR-
rNDV-18HL.
The recombinant NDV carrying cHAb18 antibody
(rNDV-18HL) was rescued using a standard protocol as
described previously [7]. Briefly, 2.5 μg of pBR-rNDV-
18HL, 1 μg of T7-NP, 1 μg of T7-P, and 0.5 μg of T7-L
were mixed and co-transfected into BSR-T7/5 cells using
Lipofectamine 2000 (Life Technologies, Carlsbad, CA).
Culture supernatant was collected at 3 days post-
transfection and the recombinant rNDV-18HL was
purified using plaque assay.
To identify recombinant rNDV-18HL, the genome
RNA of virus was extracted using MiniBEST viral RNA/
DNA extraction kit (TaKaRa Bio, Otsu, Japan) and the
foreign fragment between the HN and F genes were
amplified using primers VT-F and VT-R (Table 1). Then
PCR product was purified and sequencing for
verification.
Identification of virally expressed cHAb18 antibody
To identify rNDV-18HL-expressed cHAb18 antibody,
BHK-21 cells were infected with rNDV-18HL at MOI =
0.01. The culture supernatant was collected at 36 h post-
infection and purified using Protein G affinity chroma-
tography column (Pharmacia Inc., Peapack, USA). The
cHAb18 was detected using western blot analysis under
reduced condition, which following the standard proto-
col using anti-human IgG antibody (Fab specific) (Sigma,
Brooklyn, USA).
To quantitate the cHAb18 production at different time
points, BHK-21 cells were infected with rNDV-18HL at
MOI = 0.01 and the culture supernatants were collected
at different time of post-infection. The concentration of
cHAb18 was detected using indirect ELISA assay.
Briefly, the culture supernatants and standards were
added to the ELISA wells which were coated with
CD147 extracellular domain we produced previously
[26]. After the incubation, anti-human IgG antibody
labeled with horseradish peroxidase (Sigma, Brooklyn,
USA) was added and the concentration was measured
using Epoch microplate spectrophotometer (BioTek,
Winooski, VT).






















Fig. 1 Construction and rescue of rNDV-18HL. a Schematic diagram of the rNDV-18HL genome which contained the genes of light and heavy
chains of human-mouse chimeric antibody cHAb18. Two transcriptional cassettes containing light and heavy chains with gene start (GS) and
gene end (GE) signals were inserted into the AgeI (isoaudamers of Kpn2I) site between F and HN genes. b Syncytia cells induced by recombinant
rNDV-18HL which was rescued by co-transfection of pBR-rNDV-18HL with three helper plasmids into BSR-T7/5 cells. BSR-T7/5 cells co-transfected
with three helper plasmids were served as control. Scale bar = 200 μm
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Measurement of cHAb18 affinity for CD147
To determine the antibody affinity, cHAb18 was puri-
fied from culture supernatant using Protein G affinity
chromatography column (Pharmacia Inc, Peapack-
Gladstone, NJ). The equilibrium dissociation constant
(KD) of cHAb18 was measured by surface plasmon
resonance (SPR) technology with ProteOn™ GLC sen-
sor (Bio-Rad Inc, Hercules, CA) according to the pro-
cedure described previously [25]. The data were
analyzed using a 1:1 Langmuir binding model with
global fitting (BIAevaluation software, BIAcore,
Uppsala, Sweden).
Viral proliferation
To investigate the proliferation of rNDV-18HL, BHK-21
cells in a six-well-plate were infected with NDV (MOI =
0.01). The culture supernatant was collected at different
time of post-infection and the viral titer was measured
by end-point dilution assay (TCID50/ml). Using BHK-21
cells with eight replicates for each dilution, the TCID50
per milliliter was calculated according to the method of
Reed and Muench [27] and each assay was repeated
three times.
Cell viability
Three human HCC cell lines, HepG2, SMMC-7721, and
HuH-7 were infected with NDV at MOI = 0.01. The via-
bility of cells at different time points was assessed by
MTT cell proliferation and cytotoxicity assay kit
(Beyotime Institute of Biotechnology, Haimen, China)
with three repetitions for each sample. Absorbance at
570 nm was determined with BIO-TEK microplate
readers (BioTek Instruments, Winooski, VT).
Transwell invasion and wound healing assays
The inhibition of cell invasion and migration by
cHAb18 derived from rNDV-18HL was performed in
SMMC-7721 cells using transwell invasion and wound
healing assays according to the procedures described
previously [25]. To detect the synergistic effect of
rNDV-18HL on repression of cell migration, 2 × 104
SMMC-7721 cells were cultured in a transwell cham-
ber with 8 μm pore (Millipore, Billerica, MA) and in-
fected with rNDV-18HL at MOI = 0.01. At 3 days
post-infection, cells attached to the lower side of
membrane were wiped with sterile cotton swabs. The
medium in the upper chamber was replaced with
fresh serum-free medium. The next day cells re-
attached on the lower side were fixed with 90 %
ethanol for 3 min and stained with 0.1 % crystal vio-
let for 10 min. The stained areas were measured
using ImageJ software (National Institutes of Health,
Bethesda, MD).
Orthotopic xenograft model of human hepatoma and
oncolytic virotherapy
The 6 to 8-week-old female BALB/c nude mice were pur-
chased from Animal Resources Centre (Shanghai, China).
All mice were housed at a constant temperature (24 °C) in
pathogen-free conditions with a 12:12 h light–dark photo-
period, and allowed food and water ad libitum. The proto-
cols involving animals were conducted according to the
Animal Welfare Act and approved by the Animal Care
and Use Committee of Fourth Military Medical University
(No. 2012065). The surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to
minimize animal suffering. The 5 × 106 SMMC-7721 cells
in 100 μl matrigel (BD Bioscience) were implanted into
hepatic lobule of mice. Mice were randomized into four
groups in one week after implantation, which were re-
ceived tail intravenous injection twice weekly for 3 weeks
and denoted as saline (0.9 % NaCl), cHAb18-treated
(2 mg/kg/injection), NDV Italien-treated (5 × 107 PFU/in-
jection), and rNDV-18HL-treated (5 × 107 PFU/injection)
groups. Body weight was measured every three days since
implantation. The endpoint of observation for each mouse
was determined by the following conditions: lack of re-
sponsiveness to manual stimulation, immobility, and/or
inability to eat or drink. The mice meeting one of the cri-
teria were euthanized using pentobarbital.
Living imaging of mice
Mice were infected with 5 × 107 PFU rNDV-Luci by tail
intravenous injection every two days for three times. At
24 h post-final injection, mice were anesthetized with
isoflurane mixed with oxygen and injected intraperitone-
ally with D-luciferin potassium salt (1.5 mg/mouse) for
10 min before imaging. Bioluminescence images were
captured using Xenogen IVIS spectrum in vivo imaging
system (Caliper Life Sciences, Hopkinton, MA).
Immunohistochemistry
Mice were sacrificed and organs were fixed with 10 %
formalin followed by embedding in paraffin. Tissue sec-
tions (4 μm) were obtained from the paraffin blocks,
stained with hematoxylin and eosin (H&E) and were
subjected to immunohistochemistry by staining with
rabbit anti-NDV HN protein antibody (Bioss, San Diego,
CA), rabbit anti-human IgG Fc, or rabbit anti-Ki-67
(Abcam, Cambridge, UK) using a streptavidin-
peroxidase staining kit (ZSGB-Bio., Beijing, China).
Statistical analysis
Statistical data were obtained with SigmaPlot (Systat
Software, San Jose, CA). One-way analysis of variance
(ANOVA) was used to determine significance between
groups followed by the Dunnett’s test to analyze the
differences between treated group and control group. A
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two-tailed Student t test was applied for comparison of
two individual data. Survival analysis was determined by
Kaplan-Meier estimation and log-rank test. A P-value less
than 0.05 is considered statistically significant. Data were
presented as means plus the standard deviation (SD).
Results
Generation of recombinant NDV carrying cHAb18
antibody
The genes of light and heavy chains of cHAb18 were
introduced in the non-coding region between F and HN
to generate a recombinant plasmid pBR-rNDV-18HL
(Fig. 1a). The pBR-rNDV-18HL and the three helper plas-
mids (T7-NP, T7-P, and T7-L) [28] were co-transfected
into BSR-T7/5 cells. At 3 days post-transfection, plaques
were observed and the recombinant NDV carrying
cHAb18 (rNDV-18HL) was identified by sequencing non-
coding region between HN and F genes (Fig. 1b).
We detected the antibody level in the supernatant of
virus-infected BHK-21 cells. Western blot assay showed
an expression of IgG with 25 kDa and 55 kDa bands
under the reduced condition, which indicated the light
and heavy chains of antibody, respectively (Fig. 2a).
Sandwich ELISA showed that cHAb18 antibody could
bind the CD147 antigen and anti-human IgG antibody
simultaneously. The concentration of cHAb18 was
gradually increased with the time of viral infection which
reached the peak 7.07 μg/ml at 48 h post-infection and
then kept the platform (Fig. 2b). SPR analysis showed
that the KD of cHAb18 was 4.15 × 10
−10 M, which was
very close to the same antibody produced from genetic-
ally engineered CHO cells [25] (Fig. 2c). All these results
showed that the replication of rNDV-18HL was accom-
panied by an accelerated expression of intact cHAb18
antibody.
rNDV-18HL kept the oncolytic features as wild strain NDV
Italien
We analyzed the proliferation of rNDV-18HL in BHK-21
cells. As shown in Fig. 3a, no significant differences of
virus titer between rNDV-18HL and NDV Italien were
detected, which indicated that the insertion of cHAb18
gene did not disturb the replication capacity of NDV
and the recombinant rNDV-18HL still kept the same









































Fig. 2 Identification of rNDV-18HL. a BHK-21 cells were infected with rNDV-18HL and the human IgG was purified from the supernatant for
detecting cHAb18 expression using western blot analysis. The purified cHAb18 antibody from stably transfected CHO clone was served as control.
b The level of cHAb18 antibody was determined by ELISA in culture supernatants of rNDV-18HL-infected BHK-21 cells at different time of post-
infection (n = 5). c One-shot kinetics for the interaction between virally expressed cHAb18 antibody and CD147 antigen was detected with surface
plasmon resonance technology. Each set of five sensograms displayed the responses to the five diluted concentrations of recombinant CD147
interacting with one immobilization level of cHAb18 antibody. RU was denoted as resonance unit
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Three human HCC cell lines, HepG2, HuH-7, and
SMMC-7721 were infected with either rNDV-18HL or
NDV Italien, and the cell viability was measured by
MTT assay each day during the first week post-
inoculation. As shown in Fig. 3b, rNDV-18HL induced
the cytolysis effects with the similar features by NDV
Italien in all cell lines. HepG2 and HuH-7 cells were
more sensitive to both rNDV-18HL and NDV Italien
replication and almost dead at 7 days post-infection
compared with SMMC-7721 cells (Fig. 3c). These results
indicated that rNDV-18HL retained its oncolytic prop-
erty with diverse sensitivity to different tumor cell lines.
rNDV-18HL enhanced the inhibition of tumor cell
migration and invasion
The CHO cells-produced cHAb18 had been proved to
inhibit tumor cell invasion and migration in our
previous study [25]. Here, we verified that rNDV-
18HL-expressed cHAb18 antibody still suppressed the
migration and invasion of SMMC-7721 cells in dose-
dependent manners, as detected by wound healing
(Fig. 4a and b) and transwell invasion assays (Fig. 4c
and d). Furthermore, using transwell chamber, we
evaluated the anti-migration ability of rNDV-18HL.
At 4 days post-infection, most cells were destroyed by
rNDV-18HL or NDV Italien directly, meanwhile, the
migration of relict cells were inhibited significantly in
rNDV-18HL-treated cells compared with that of NDV
Italien (Fig. 4e and f ). Because rNDV-18HL and NDV
Italien had the same oncolytic property as demon-
strated in Fig. 3, we believed that the anti-motility ef-
fect was caused by the expression of cHAb18
antibody.
rNDV-18HL specifically replicated in orthotopic HCC
xenografts leading to cHAb18 antibody expression in situ
and tumor central necrosis
To evaluate the selective replication of rNDV-18HL
in tumors, a model of human HCC xenograft in
athymic nude mice was established by orthotopic liver
transplantation. The recombinant rNDV-Luci was
injected into the mice via tail vein. At 3 days post-
infection, luminescence was detected in the epigastric
regions in tumor-bearing mice using in vivo imaging
system (Fig. 5a). Autopsy findings indicated the tumor
formation in livers, and it seemed that the larger
tumor loci (#1) had a stronger luminescence intensity
than the smaller one (#2) (Fig. 5a and b). Immuno-
histochemistry assay detected that the NDV distribu-
tion was limited in the tumors (Fig. 5c).
Next, the orthotopic HCC xenograft athymic mice
were intravenously treated with rNDV-18HL and




























































Fig. 3 Characteristics of rNDV-18HL. a Proliferation dynamic of rNDV-18HL. BHK-21 cells were infected with either rNDV-18HL or NDV Italien at
MOI = 0.01. At 6, 12, 24, 36, 48, and 72 h post-infection, culture supernatants were collected and the viral titer was determined (TCID50/ml) (n = 3).
b Cytotoxicity assay of rNDV-18HL. SMMC-7721, HuH-7, and HuH-7 cells were infected with either rNDV-18HL or NDV Italien for 7 days. The cell
viability was measured using MTT assay (n = 5). The cell viability of the three HCC cell lines at 7 days post-infection was shown in (c)
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sacrificed at 24 h post-injection. Using consecutive tis-
sue sections, immunohistochemistry analysis showed
that both NDV and cHAb18 expression were only
presented in the tumor tissues of mice injected with
rNDV-18HL (Fig. 5d), while the virus was spare in
normal organs (Fig. 5e). The replication of rNDV-18HL
in tumor not only facilitated antibody expression, but
also induced tumor tissue necrosis as detected by H&E
staining and anti-Ki-67 staining. Antigen Ki-67, a cellu-
lar marker for proliferation, is present during all active
phases of the cell cycle, but is absent from resting cells.
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Fig. 4 The inhibition of HCC cell motility by virally expressed cHAb18 and rNDV-18HL. a Wound healing assay detected the migration of SMMC-
7721 cells which were treated with virally expressed cHAb18 for 24 h. b The relative wound closure was measured using ImageJ (n = 5). Scale
bar = 500 μm. c SMMC-7721 cells in transwell chamber coated with matrigel were treated with virally expressed cHAb18 for 24 h. The invaded
cells were stained with crystal violet. Scale bar = 200 μm. d The invaded cells were quantified by determining the absorption at 570 nm (n = 3).
e Transwell migration assay detected the migration of SMMC-7721 cells which were treated with either rNDV-18HL or NDV Italien. The cells on
the lower side of membrane were stained with crystal violet. Scale bar = 200 μm. f The stained area of each image was measured using ImageJ
(n = 5). * P < 0.05, ** P < 0.01, *** P < 0.001
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observed in the tumor margin in both virus-treated
groups with proliferating and hematoxylin-positive cells
distributed sporadically. Whereas, in saline group,
Ki-67-positive cells were displayed on tumor margin
and center region as well as. No necrosis was observed
(Fig. 5d). These results suggest that recombinant NDV
Italien infected tumor tissue effectively and replicated
in tumor cells selectively leading to the exogenous
antibody gene expression and tumor central necrosis.
rNDV-18HL reduced the intrahepatic metastasis and
prolonged the survival in mice
To investigate the synergistic effects of rNDV-18HL on
anti-tumor activity, intrahepatic metastatic foci were
checked. As shown in Fig. 6a and b, mice treated with
rNDV-18HL at 24 h post-treatment had less metastatic foci
compared with NDV Italien (P < 0.05) or saline (P < 0.01),
while no differences of metastatic foci between NDV Italien
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Fig. 5 Tumor-selective replication of rNDV-18HL in orthotopic HCC xenograft mice induced tumor necrosis and cHAb18 antibody expression in
situ. a Orthotopic HCC xenograft nude mice were treated intravenously with rNDV-Luci. At 24 h post-injection, the mice were anesthetized and
visualized by luminescence using Xenogen IVIS spectrum. The exposure time was 1 min, and the images were pseudocolored according to the
scale on the right. b The mice were sacrificed and dissected to identify the location of tumors in the livers (arrow). c Tumor-bearing livers were
excised (top) and the tissue sections were stained with rabbit anti-NDV HN protein antibody to indicate the distribution of NDV (bottom). Scale
bar = 100 μm (d) Orthotopic HCC xenograft nude mice were treated intravenously with either rNDV-18HL or NDV Italien twice weekly for 3 weeks.
The mice were sacrificed and the tumor-bearing livers were excised. The consecutive tissue sections were used for visualizing tumor loci by H&E
staining, and detecting NDV, cHAb18 antibody, and Ki-67 expression by immunohistochemistry. The tumor tissue necrosis was indicated by red
line. Scale bar = 200 μm. e Normal organs were also excised and stained with anti-NDV HN monoclonal antibody to detect the distribution of
NDV. Scale bar = 200 μm
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The survival curves and log rank test showed that
rNDV-18HL treatment significantly prolonged the
survival in mice (P = 0.035) (Fig. 6c). Meanwhile, there
was no significant difference of survival among NDV
Italien, cHAb18, and saline groups although beneficial
trends were detected in cHAb18 and NDV Italien-
treated groups, which was similar to our previous
studies [7, 25]. The results suggested that oncolytic
NDV carrying cHAb18 antibody improved therapeutic
effects by inhibiting tumor local metastasis contribut-
ing to the survival. The body weights of rNDV-18HL-
treated group showed continuous increase during the
period of observation, and NDV Italien-treated group
was stable, while the cHAb18-treated and saline
groups displayed downtrends after 26 days post-
treatment (Fig. 6d). As the body weight loss could be






























































































Fig. 6 Enhanced anti-tumor effect of rNDV-18HL. a Orthotopic transplantation HCC nude mice were treated with rNDV-18HL, NDV Italien, or
normal saline through tail intravenous injection twice weekly for 3 weeks. At 24 h post-injection, three mice of each group were sacrificed to
investigate the metastatic foci in the liver. The representative images were shown by gross observation (upper) and Ki-67 staining (bottom).
b The number of metastatic foci was counted (three Ki-67 staining slides were selected randomly for each sample, and only separated metastatic
foci bigger than 50 μm was counted) and indicated as means ± SD. * P < 0.05, ** P < 0.01. c Orthotopic transplantation HCC nude mice were
treated with rNDV-18HL, cHAb18, NDV Italien, or normal saline through tail intravenous injection twice weekly for 3 weeks. The number of mice
in each group was 11. The treated mice were monitored daily and the Kaplan-Meier survival curve was plotted and analyzed by log-rank test.
d The body weights were recorded every 3 days after treatment
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caused by tumor progression and treatment-induced
side-effects, our data revealed a benefit of rNDV-
18HL treatment and less side-effect.
Discussion
The “armed” OVs which combine gene therapy, im-
munotherapy, and oncovirotherapy are regarded as
potential and promising agents for tumor therapy. Cy-
tokines and therapeutic genes are desirable exogenous
genes to enhance anti-tumor activity of OVs [29–31].
Several genes, such as interferon [32], tumor necrosis
factor-related apoptosis inducing ligand (TRAIL) [33],
interleukin-7 (IL-7) [34], cytosine deaminase [35], IL-
2 [33, 36], GM-CSF [37], and IL-15 [38] have been
reported to be incorporated into lentogenic strains of
NDV genome. A proof-of-principle study demon-
strates the transgenic expression of a full IgG anti-
body recognizing ED-B type III of fibronectin by
mesogenic NDV strain MTH68 [39]. Here, we con-
structed a recombinant velogenic NDV strain Italien
carrying humanized therapeutic antibody to enhance
the therapeutic effect of tumor therapy. We intro-
duced the cHAb18 antibody between the F and HN
genes using two independent transcriptional cassettes
to express heavy and light chains of antibody. The
insertion of antibody gene into this site struck a
balance between the expression level of exogenous
gene and the viral proliferation. It is reported that
administration of antibodies carries the risk of some
adverse effects, including infusion reaction, cardio
toxicity, and hypersensitivity, which can cause a
serious problem even death [40]. We supposed that
the tumor-selective delivery of antibodies by oncolytic
NDV limited the virus spreading into circulation
system or normal organs, which might facilitate to di-
minish the side effects of antibody drug our previous
study, it is proved that cHAb18 antibody directs against
CD147 to inhibit matrix metalloproteinase-2/9 production
and rearrange actin cytoskeleton via suppressing integrin-
FAk-PI3K/Akt-girdin signaling pathway, thus suppressing
cell invasion and motility [25]. Our study indicated that
the recombinant rNDV-18HL combined the oncolytic vir-
otherapy and antibody therapy which showed an increased
antitumor activity than NDV Italien or cHAb18 antibody
alone. On the one hand, rNDV-18HL infected tumor
cells specifically and caused tumor lysis directly. On
the other hand, virally expressed cHAb18 which was
released from the lysate of tumor cells inhibited the
metastasis of tumor cells.
Conclusions
The recombinant NDV carrying the chimeric cHAb18
monoclonal antibody improves the therapeutic effect
and shows a new strategy for tumor therapy.
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